Stocks › MDGL
MADRIGAL PHARMACEUTICALS, INC.
MDGL·Nasdaq·
United States·USD
$379.10
-17.64 (-4.45%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
MDGL
MADRIGAL PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
MDGLS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of MDGL by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Daniel S. GoldmanHouse · D · NY |
MDGLMADRIGAL PHARMACEUTICALS, INC. · Stock |
Sale $1,001 - $15,000 |
May 19, 2023 | Apr 10, 2023 | Filing ↗ |
Whale Activity
Position changes in MDGL reported for 2026-09-30 by 491 institutional filers
- Increased156
- New77
- Held62
- Decreased126
- Closed49
- No prior filing21
| Filer | Shares | Value | Change |
|---|---|---|---|
| BAKER BROS. ADVISORS LP | 2.1M | $1.08B | held |
| Janus Henderson Group Ltd. | 2.0M | $993.9M | — |
| Avoro Capital Advisors LLC | 1.8M | $923.9M | held |
| PAULSON & CO. INC. | 1.5M | $751.7M | increased |
| BlackRock, Inc. | 1.2M | $624.4M | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 928.8K | $468.1M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 846.6K | $426.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 761.0K | $383.5M | decreased |
| AQR CAPITAL MANAGEMENT LLC | 636.2K | $320.6M | increased |
| STATE STREET CORP | 595.8K | $300.2M | increased |
| AMERIPRISE FINANCIAL INC | 448.4K | $226.0M | — |
| GEODE CAPITAL MANAGEMENT, LLC | 368.8K | $185.9M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by MDGL insiders, by quarter · Form 4
Recent Insider Transactions
961 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Kelley Shannon TGeneral Counsel | Sale | −1,077 | $400.00 | $431K | Nov 6, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director | Purchase | +60.4K | $383.01 | $23.1M | Nov 6, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director | Purchase | +2,000 | $396.61 | $793K | Nov 6, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director | Purchase | +13.7K | $388.29 | $5.3M | Nov 6, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director | Purchase | +5,586 | $366.99 | $2.1M | Nov 4, 2026 | Form 4 ↗ |
| BAKER BROS. ADVISORS LP / Baker Bros. Advisors (GP) LLC / BAKER FELIX / BAKER JULIAN / 667, L.P. / Baker Brothers Life Sciences LPDirector · Director | Purchase | +10.1K | $368.11 | $3.7M | Nov 4, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −120 | $546.38 | $66K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −761 | $544.83 | $415K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −1,539 | $544.02 | $837K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −1,202 | $542.60 | $652K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −368 | $541.64 | $199K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −687 | $540.59 | $371K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −160 | $537.62 | $86K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −218 | $535.94 | $117K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −106 | $534.06 | $57K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −60 | $533.09 | $32K | Sep 11, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −160 | $542.55 | $87K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −362 | $541.65 | $196K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −505 | $540.19 | $273K | Sep 9, 2026 | Form 4 ↗ |
| Sibold William JohnPresident and CEO · Director | Sale | −215 | $539.03 | $116K | Sep 9, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding MDGL · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 585.0K | $314.1M | 0.01% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 563.1K | $263.2M | 0.69% | Jul 31, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 423.1K | $227.2M | 0.12% | Jun 30, 2026 |
| Janus Henderson Forty Fund Janus Investment Fund | 338.6K | $181.8M | 0.76% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 243.7K | $130.8M | 0.28% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund Janus Investment Fund | 233.3K | $125.3M | 0.56% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 216.9K | $116.5M | 0.12% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 211.3K | $113.4M | 1.06% | Jun 30, 2026 |
| Janus Henderson Contrarian Fund Janus Investment Fund | 168.3K | $90.3M | 1.65% | Jun 30, 2026 |
| VANGUARD EXPLORER FUND | 190.1K | $88.9M | 0.40% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list MDGL's shares (CUSIP 558868105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Roderick WongSCHEDULE 13G/A · passive (13G) · 312.8K shares1.4%
Nov 16, 2026 · ↗ - RTW Investments, LPSCHEDULE 13G/A · passive (13G) · 312.8K shares1.4%
Nov 16, 2026 · ↗ - Felix J. BakerSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
Nov 6, 2026 · ↗ - Julian C. BakerSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
Nov 6, 2026 · ↗ - Baker Bros. Advisors (GP) LLCSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
Nov 6, 2026 · ↗ - Baker Bros. Advisors LPSCHEDULE 13D/A · activist (13D) · 2.3M shares10.0%
Nov 6, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 1.1M shares4.6%
Jul 29, 2026 · ↗ - JANUS HENDERSON GROUP PLCSCHEDULE 13G/A · passive (13G) · 2.0M shares8.8%
May 15, 2026 · ↗ - PAULSON & CO. INC.SCHEDULE 13G/A · passive (13G) · 1.4M shares6.1%
May 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming madrigal pharmaceuticals as client
- CAPITOL COUNSEL LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · HCR, MED, MMM$60K
Filing ↗ - MADRIGAL PHARMACEUTICALS, INC.MADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · MMM, HCR$350K
Filing ↗ - CROSSROADS STRATEGIES, LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · HCR, MMM$50K
Filing ↗ - BALLARD PARTNERS, LLCMADRIGAL PHARMACEUTICALS, INC. · 2026 Q3 · PHA$120K
Filing ↗ - MADRIGAL PHARMACEUTICALS, INC.MADRIGAL PHARMACEUTICALS, INC. · 2026 Q2 · MMM, HCR$380K
Filing ↗
Government Contracts
Federal awards to madrigal pharmaceuticals · USAspending
$30KAwarded · 1 contract on record
- Department of Veterans AffairsREZDIFFRA 80 MG$30K
Jun 5, 2026 · ↗
U.S. Patents
Recent USPTO applications naming MADRIGAL PHARMACEUTICALS, INC.
No USPTO patent applications found for MADRIGAL PHARMACEUTICALS, INC..
Annual Financials
From MDGL's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 |
| Operating income | -$300.1M | -$497.9M | -$380.5M | -$293.6M | -$242.5M |
| Net income | -$288.3M | -$465.9M | -$373.6M | -$295.4M | -$241.8M |
| Diluted EPS | -$12.85 | -$21.90 | -$19.99 | -$17.23 | -$14.63 |
| Operating cash flow | -$189.6M | -$455.6M | -$324.2M | -$224.9M | -$183.9M |
| Cash and equivalents | $198.7M | $100.0M | $99.9M | $331.5M | $36.3M |
| Total assets | $1.26B | $1.04B | $640.5M | $362.6M | $273.3M |
| Total liabilities | $656.9M | $287.9M | $235.2M | $165.2M | $77.2M |
| Shareholders' equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M |
As MADRIGAL PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 19, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 1-for-35Reverse splitJul 25, 2016
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 3, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureAug 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 6, 2026
EDGAR ↗
About MADRIGAL PHARMACEUTICALS, INC.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersWEST CONSHOHOCKEN, PA
IncorporatedDE
SEC CIK0001157601 ↗
Former namesMADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP

